Nubeqa (darolutamide) Receives Third Approval in China for Men With Advanced Prostate Cancer
February 04, 2026
February 04, 2026
LEVERKUSEN, Germany, Feb. 4 -- Bayer, a pharmaceutical and life sciences company, issued the following news release on Feb. 3, 2026:
* * *
Nubeqa (darolutamide) receives third approval in China for men with advanced prostate cancer
Darolutamide is now the first and only androgen receptor inhibitor (ARi) approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ( . . .
* * *
Nubeqa (darolutamide) receives third approval in China for men with advanced prostate cancer
Darolutamide is now the first and only androgen receptor inhibitor (ARi) approved in China for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy ( . . .